Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04671251
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
13
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
AEVI-007
Sponsor
Avalo Therapeutics, Inc.